Asieris Pharmaceuticals

50 articles about Asieris Pharmaceuticals

• Asieris Pharmaceuticals Unveils 2023 Annual Report, Core Product APL-1702 Succeeds in Global Phase III Clinical Trials, APL-1706 obtains NDA acceptance domestically, Specialty Commercial Team Generates Sustained Revenue Streams

  4/17/2024

  Asieris Pharmaceuticals released its 2023 Annual Report, revealing impressive outcomes achieved through its specialty pharma strategy, which has facilitated rapid progress in clinical development, early research, and commercialization.

• 

  5 Successful Phase III Oncology Trials in Q1

  4/8/2024

  2024 began with several biopharma players posting positive Phase III data that could mean new market share for the companies and longer survival times and quality of life for patients.

• Breakthrough in Treatment of Cervical High-Grade Squamous Intraepithelial Lesion: Release of Positive Results from Multicenter Phase III Global Clinical Study

  3/19/2024

  Asieris Pharmaceuticals announced that the multicenter Phase III global clinical study data of its non-surgical treatment for cervical HSIL product APL-1702 demonstrated significant efficacy and good safety profile, with new advancements in clearance rate of high-risk HPV16 and/or HPV18.

• Photocure Partner Asieris to present First-ever Results of the international multicenter Phase III clinical Study for Cevira, a non-surgical treatment for cervical HSIL, at the 2024 EUROGIN

  2/22/2024

  Photocure ASA announces that its partner Asieris Pharmaceuticals has communicated that the international multicenter Phase III clinical study of Cevira®, the non-surgical treatment in development for cervical high-grade squamous intraepithelial lesions, will be presented for the first time in the form of an oral presentation at the 2024 European Research Organization on Genital Infection and Neoplasia, held March 13-16 in Stockholm, Sweden:

• Asieris Releases Phase III Clinical Study and Real-World Research Data for APL-1706, a Bladder Cancer Diagnosis and Management Drug, at the 2024 ASCO-GU

  1/29/2024

  Asieris Pharmaceuticals announced the release of Phase III clinical trial data and real-world study data for APL-1706, a bladder cancer diagnosis and management drug, at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium in the form of a poster presentation.

• Asieris Presents for the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

  1/29/2024

  Asieris Pharmaceuticals announced the first-time release of interim analysis data for the Phase II clinical trial of oral APL-1202 in combination with the PD-1 inhibitor tislelizumab for neoadjuvant treatment of muscle-invasive bladder cancer.

• Asieris will Present For the First Time Interim Analysis Data of Oral APL-1202 in Combination with PD-1 Inhibitor Tislelizumab for Neoadjuvant Treatment of Muscle-Invasive Bladder Cancer at 2024 ASCO-GU

  1/25/2024

  Asieris Pharmaceuticals announced that the interim analysis data from the Phase II clinical trial of oral APL-1202 in combination with PD-1 inhibitor tislelizumab as neoadjuvant therapy for muscular invasive bladder cancer will be presented for the first time in the form of a rapid oral presentation abstract at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium.

• Enhancing Leadership in Gynecology, Asieris Pharmaceuticals Appoints Sophia Cao to Lead the Newly-Established Women's Health Business Unit, Accelerating Strategic Expansion

  1/9/2024

  Asieris Pharmaceuticals has announced its set-up of the Women's Health Business Unit for commercialization.

• APL-2301, a compound developed by Asieris for the treatment of Acinetobacter baumannii infection, was approved for Phase I clinical trials in Australia

  12/24/2023

  Asieris Pharmaceuticals announced that its product, APL-2301, used for the treatment of Acinetobacter baumannii infections, was approved for Phase I clinical trials in Australia.

• Asieris Unveiled Results of Its Phase III Clinical Study for APL-1706, an Imaging Drug for Diagnosis or Surgery of Bladder Cancer, at the SIU 2023 Congress

  10/12/2023

  Asieris Pharmaceuticals has unveiled its phase III clinical trial data for APL-1706 (Hexvix ® ), an imaging drug used for the diagnosis or surgery of bladder cancer, at the 43rd  Congress of the Société Internationale d'Urologie (SIU) in 2023.

• The First Non-Vaccine Investigational Product for Cervical HSIL has Achieved Its Primary Endpoint

  9/20/2023

  Asieris Pharmaceuticals has announced that the multinational Phase III clinical trial of APL-1702, a novel, non-surgical treatment of cervical high-grade squamous intraepithelial lesions, has met its primary endpoint.

• Asieris Announces Positive Interim Analysis Results in Phase II Clinical Trial of Oral APL-1202 in Combination with Tislelizumab, a PD-1 inhibitor, as Neoadjuvant Therapy for Muscle Invasive Bladder Cancer

  9/13/2023

  Asieris Pharmaceuticals announced that the clinical trial of oral APL-1202 in combination with PD-1 inhibitor Tislelizumab as neoadjuvant therapy for muscular invasive bladder cancer (MIBC) completed the phase II interim analysis with positive results.

• Asieris Obtained IND Approval from NMPA for APL-1401, a Drug for the Treatment of Moderately-to-Severely Active Ulcerative Colitis

  8/30/2023

  Asieris Pharmaceuticals announced that the National Medical Products Administration has approved the Investigational Drug application for its oral drug APL-1401 for the treatment of moderately-to-severely active ulcerative colitis.The IND application had previously been approved by the U.S. Food and Drug Administration.

• Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

  8/22/2023

  Asieris Pharmaceuticals released its 2023 Semi-Annual Report that highlights the accelerated progress in clinical trials, aiming to address the field's highly unmet diagnostic and therapeutic needs.

• Hong Kong Department of Health has Approved the Registration Applications for the Uro-G and Uro-V Disposable Cystoscopic System

  8/15/2023

  Asieris Pharmaceuticals announced that the Government of Hong Kong Special Administrative Region Department of Health has approved the registration applications for the Uro-G and Uro-V disposable cystoscopic system.

• Asieris Announces Positive Phase III Bridging Trial of Hexvix®, a Diagnostic Drug for Bladder Cancer

  8/11/2023

  Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced that the Phase III bridging clinical trial of Hexvix® for bladder cancer diagnosis met the primary endpoint.

• Hexvix®, A Diagnostic Drug for Bladder Cancer of Asieris has Completed the Phase III bridging trial Enrollment

  7/6/2023

  Asieris Pharmaceuticals announced the completion of patient enrollment for its Phase III bridging clinical trial of Hexvix®, a drug used for the diagnosis of bladder cancer.

• Asieris' progress in MIBC receives renewed attention with its inclusion in ASCO 2023

  5/31/2023

  Asieris Pharmaceuticals announced the phase I clinical data of ANTICIPATE Study was published for the first time at the 2023 American Society of Clinical Oncology annual meeting in Chicago.

• Asieris Deepens Strategic Partnership with UroViu to Further Develop Integrated Diagnosis and Treatment Platform for Bladder Cancer

  5/18/2023

  Asieris Pharmaceuticals, a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and other related diseases, announced a strategic collaboration with UroViu Corporation.

• Asieris Releases 2022 Annual Report: Makes Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

  4/17/2023

  Asieris Pharmaceuticals, a global biopharma company specializing in the discovery, development and commercialization of innovative drugs that treat genitourinary tumors and other related diseases, released its 2022 annual report.